NCT02584309View on ClinicalTrials.gov

Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 22, 2016

Primary Completion Date

July 17, 2022

Study Completion Date

July 17, 2022

Conditions

Sarcoma, Soft TissueSoft Tissue SarcomaUndifferentiated Pleomorphic SarcomaLeiomyosarcomaLiposarcomaSynovial SarcomaMyxofibrosarcomaAngiosarcomaFibrosarcomaMalignant Peripheral Nerve Sheath TumorEpithelioid Sarcoma

Interventions

DRUG

Dexrazoxane

DRUG

Doxorubicin

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors

lead

Washington University School of Medicine

OTHER

NCT02584309 - Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma | Biotech Hunter | Biotech Hunter